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Background: On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of
advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with
S-1 plus cisplatin (SP), which is considered standard therapy in Japan, has not yet been assessed.
Methods/design: This is a multicenter randomized phase II trial to elucidate the efficacy of XP as compared with
SP for first-line treatment of advanced gastric cancer. Patients with unresectable metastatic or recurrent gastric
cancer, 20–74 years of age and human epidermal growth factor 2 (HER2)-negative status, will be assigned in a 1:1
ratio to receive either S-1 40 mg/m2 bid for 21 days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle or
capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle. Patients will be also
asked to the analysis of tumor tissues for translational investigations. The Primary endpoint is progression-free
survival and secondary endpoints are overall survival, time to treatment failure, tumor response rate and safety.
These comparisons will also be evaluated in terms of biomarkers. Planned sample size is 100 (50 in each arm),
which is appropriate for this trial.
Discussion: Fluoropyrimidine plus cisplatin combination is the standard regimen of the first line treatment for
advanced gastric cancer. Both S-1 and capecitabine are the prodrug of 5-FU but differ from their process of
metabolism. Result of this trial and translational research will provide the important clues to prepare the
individualized therapy for advanced gastric cancer in the near future.
Trial registration: ClinicalTrials.gov Identifier NCT01406249
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Gastric cancer is the fourth most common malignancy in
the world (988 602 cases in 2008, 7.8% of total) and the sec-
ond leading cause of cancer death (737 419 deaths, 9.7% of
total) [1]. For the treatment of advanced or recurrent gastric
cancer (AGC), the most commonly used regimens are com-
bination chemotherapy consisting of a fluoropyrimidine
(5-fluorouracil or oral fluoropyrimidine) plus a platinum
agent with or without docetaxel or anthracyclines [2-6].
S-1 is an oral anticancer drug composed of the
5-fluorouracil (5-FU) prodrug tegafur and two 5-FU mod-
ulators; it has achieved high response rates in patients with
gastric cancer in phase II studies [7,8]. In a phase III trial
(SPIRITS trial) that compared S-1 alone to S-1 plus cis-
platin (SP), SP showed a significantly longer overall sur-
vival (OS; 13 months vs. 11 months; HR= 0.77, 95% CI
0.61–0.98, p = 0.04) and longer progression-free survival (PFS;
6.0 months vs. 4.0 months; HR= 0.57, 95% CI 0.44–0.73,
p < 0.0001) [4]. Therefore, SP is now considered to be one
of the standard first-line regimens for AGC in Japan.
Capecitabine is also an oral fluoropyrimidine, which is
metabolized primarily in the liver and converted in tumor
tissues to 5-FU by the enzyme thymidine phosphorylase
(TP), which is associated in higher concentrations in
tumor cells than in normal cells [9]. Kang and colleagues
evaluated the non-inferiority of capecitabine plus cisplatin
(XP) compared with 5-FU plus cisplatin (FP). The median
PFS showed significant non-inferiority (5.6 months vs.
5.0 months; HR= 0.81, 95% CI 0.63–1.04, P < 0.001) [5]. On
the basis of these results, XP is now considered one of the
standard treatments of AGC [10], and XP was adopted as
the reference arm in two recent global studies of molecular
targeting agents [11,12]. However, data is scarce with respect
to XP treatment in Japanese patients, and also the usefulness
of XP as compared with SP has not yet been assessed.
As another issue, these 2 types of oral fluoropyrimidine
show some different characteristics in the mechanisms of
their antitumor effect. A subset analysis of the FLAGS
trial showed that S-1 seemed to be better than 5-FU in
the subgroup with diffuse-type gastric cancer [6]. This re-
sult was consistent with the results of a subset analysis of
the JCOG9912 trial, which showed that S-1 was better
than 5-FU in patients with diffuse-type gastric cancer or
with gastric cancer associated with high dihydropyrimi-
dine dehydrogenase (DPD), with diffuse-type tumors
associated more commonly than intestinal type with high
DPD [13]. This result was expected, since S-1 consists of
tegafur, otastat potassium, and gimestat which is a potent
competitive inhibitor of DPD. Capecitabine is trans-
formed to 5-FU in several steps, to be finally converted
by TP as above [9]. A phase II trial in Japan showed that
response rate (RR) was significantly higher (Fisher’s exact
test, p = 0.028) in patients with TP-positive and DPD-
negative tumors (60%, 6/10) than in the remainingpatients (13%, 2/15) [14]. In contrast, high expression of
TP is reported to be negatively associated with efficacy of
5-FU or S-1 in gastric cancer [15,16].
On the basis of the above reports, histological type
(diffuse or intestinal) and biomarkers (TP, DPD, and others)
may be candidates to select whether S-1 or capecitabine be
used for each patient, although validation with a rando-
mized study is necessary. We planned the current clinical
trial to elucidate the efficacy of XP and SP for the first-line
treatment of AGC. This comparison will be also evaluated
in terms of several biomarkers.
Method/design
Study objective
This randomized phase II trial is planned to elucidate
the efficacy of SP and XP and also to explore predictive
or prognostic biomarkers with additional research. This
trial protocol has been approved by the Institutional Re-
view Board (IRB) of each participating institution and
the Kanagawa Cancer Center.
Study endpoints
Primary endpoint is PFS and secondary endpoints are
OS, RR, time to treatment failure (TTF), and incidence
of adverse events (safety).
Eligibility criteria
Inclusion criteria
(i) Histologically confirmed gastric adenocarcinoma
with unresectable metastatic or recurrent disease
(ii) Lesions confirmed by imaging no more than 28 days
before registration (not required for measurable
lesions as defined in RECIST version 1.1)
(iii) No previous chemotherapy or radiotherapy.
However, prior adjuvant chemotherapy is allowed if
more than 6 months has passed since the end of
adjuvant chemotherapy
(iv) Eastern Cooperative Oncology Group (ECOG)
Performance Status of 0, 1, or 2
(v) Life expectancy of at least 3 months after
registration
(vi) Written informed consent
(vii)Between the ages of 20 and 74 years at the time
informed consent is obtained
(viii)Adequate major organ function including:
(a) Neutrophil count: ≥1500/mm3
(b) Platelet count: ≥10.0 × 104/mm3
(c) Hemoglobin: ≥9.0 g/dL
(d) AST, ALT: ≤2.5 × upper limit of normal (ULN) in each
institution (≤5 times in cases of metastases to liver)
(e) ALP: ≤2.5 × ULN in each institution (≤5 times in
cases of metastases to liver, and ≤10 times in cases
of metastases to bone)
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(g) Creatinine clearance: ≥60 mL/min (as estimated by
Cockcroft-Gault equation)
Exclusion criteria
(i) HER2- positive status
(ii) Previous history of fluoropyrimidine therapy
within 6 months prior to registration
(iii) Previous treatment with platinum agents within
12 months prior to registration
(iv) Previous treatment with cisplatin more than total
dose of 120 mg/m2
(v) Previous history of serious hypersensitivity to
fluoropyrimidines or platinum agents
(vi) Previous history of adverse reactions suggestive of
dihydropyrimidine dehydrogenase (DPD) deficiency
(vii) More than 1 cancer at the same time or more than
1 cancer at different times separated by a 5-year
disease-free interval. However, multiple active
cancers do not include carcinoma in situ or skin
cancer which is determined to have been cured as a
result of treatment.
(viii) Obvious infection or inflammation (pyrexia ≥38.0°C)
(ix) Active hepatitis
(x) Heart disease that is serious or requires
hospitalization, or history of such disease within
the past year
(xi) Having a complication that is serious or requires
hospitalization (intestinal paralysis, intestinal
obstruction, interstitial pneumonia or pulmonary
fibrosis, poorly controlled diabetes mellitus, renal
failure, liver disorders, or hepatic cirrhosis)
(xii) Being treated or in need of treatment with
flucytosine, phenytoin, or warfarin potassium
(xiii) Chronic diarrhea (watery stools or ≥4 times/day)
(xiv) Active gastrointestinal bleeding
(xv) Body cavity fluids requiring drainage or other
treatment
(xvi) Clinical suspicion or previous history of metastasis
to brain or meninges
(xvii) Women who are pregnant, breastfeeding, or
potentially (hoping to become) pregnant
(xviii) Unwillingness to practice contraception
(xix) Poor oral intake
(xx) Psychiatric disorders which are being, or may
need to be, treated with psychotropics
(xxi) Otherwise determined by investigators or site
principal investigators to be unsuitable for
participation in study
Registration
Physicians or coordinators will send a Case Registration
Form to the data center (Epidemiological and ClinicalResearch Information Network, ECRIN) with all the
required items filled out. Enrollment has started from
July 2011.
Startification
Eligible patients will be randomized to either Arm-A
(SP treatment) or Arm-B (XP treatment) by dynamic al-
location via a centralized randomization method using 5
stratification factors as balancing variables:
(i) baseline ECOG Performance Status (0–1/2)
(ii) measurable lesion (yes/no)
(iii) prior adjuvant chemotherapy (yes/no)
(iv) histopathological classification (intestinal/diffuse)
(v) institution.
Statistical analysis
PFS has been set as the primary endpoint and is defined as
the time from date of registration until the date that pro-
gression is determined or the date of death for any reason,
whichever is sooner. “Progression” will be evaluated on the
basis of Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1 [17]. More information about the def-
inition of PFS and Progression are pre-specified (Table 1).
The primary objective of this trial is to evaluate the PFS
of SP and XP as the first-line treatment for advanced gas-
tric cancer. The 24-week progression-free rate (PFR) will
be estimated for each group, calculating point estimates
and 2-sided 90% confidence intervals. The 2-sided 90%
confidence interval of the difference between the 2 groups
will be also estimated. Exploratory analysis will be done to
test the null hypothesis that PFS is equal in both groups.
Cumulative PFS curves will be constructed as time-to-
event plots by the Kaplan-Meier method.
With respect to secondary endpoints, efficacy endpoints
OS and TTF will be evaluated according to the method of
analysis of the primary endpoint. Overall response rate
(RR) is defined as the proportion of patients with complete
response (CR) or partial response (PR) by RECIST out of
the patients with measurable lesions, and the chi-square
test will be used to compare the 2 groups. The 2-sided 95%
confidence interval of the difference between the 2 groups
will also be estimated. For the analysis of safety, Fisher’s
exact test will be used if necessary, and the exact confidence
intervals for the binomial distribution will be estimated.
Sample-size calculation
Assuming a threshold 24-week PFR of 40% and an
expected 24-week PFR of 55% (clinically promising), and
a 1.5-year registration period and a 1.5-year follow-up
period, 49 patients are required in each group to ensure a
1-sided alpha of 5% and statistical power of 90%. Assuming
that the 24-week PFR of the biomarker-positive (any FU-
related enzyme or expression of intestinal type) population
Table 1 Definition of PFS and progression
Definition of PFS and progression are predefined as below
1.) PFS will be determined as the time from the date of registration
until the date that progression is determined or the date of death
for any reason, whichever is sooner.
2.) “Progression (PD)” means both PD confirmed by routine diagnostic
imaging in each course and PD confirmed by as-needed diagnostic
imaging in the case that there is clinical suspicion of PD. In the
latter case, it is preferable that there is at least objective evidence.
3.) When progression is determined based on diagnostic imaging, the
date of progression will be the date on which imaging is assessed.
When clinical progression is first determined independently of
diagnostic imaging, and then later objectively determined on the
basis of diagnostic imaging, the date of progression will be back-
dated to the date of determination of clinical progression. If no
objective evidence is obtained, it will be treated as a censoring
event in the formal analysis, and sensitivity analysis will be also
conducted as if this were PD.
4.). When considering tumor regrowth and determining PD according
to RECIST, it is considered a PD as PFS event regardless of tumor
diameter. But even if it is decided as PD according to RECIST,
investigators can continue the protocol treatment if they consider
continued treatment to be beneficial to the patient.
5.) If treatment discontinuation is needed due to symptomatic
deterioration without any objective evidence at that time, it is
reported as “symptomatic deterioration”. Investigators should
endeavor to obtain objective evidence of the progression even
after discontinuation of treatment. In this case, the event shall be
judged to be clinical PD and handled as mentioned in 2) above.
When progression is determined on the basis of diagnostic
imaging, the date of progression will be back-dated to the date of
diagnosis of symptomatic deterioration.
6.) Survivors for whom progression has not been determined will be
censored based on the last date on which the absence of
progression was clinically confirmed (the last day that PFS was
confirmed).
7.) Cases of discontinuation of protocol treatment because of toxicity
or patient refusal, even if another therapy is added as a post-
treatment, will be censored at the date of discontinuation or the
date that post-treatment was started.
8.) In cases where progression is diagnosed on the basis of imaging,
the event will be determined based not on evaluation dates where
the result is “suspected” on imaging but on a subsequent
evaluation date where progression is “confirmed” on imaging.
9.) Secondary cancer (multiple cancers in metachronous) will not be
regarded as either an event or censored.
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arm is 40%, 46 patients in total are needed to ensure a
2-sided alpha of 10% and statistical power of 70%. Under
the hypothesis that the targeted biomarker-positive popula-
tion is 50%, 92 patients in total are required. Considering
the likelihood of some ineligible cases in the whole setting
outlined above, the total sample size is set to 100. A follow-
ing Phase III study will be designed for both randomized
comparison and biomarker-oriented comparison of XP
and SP (4 groups).
Treatment program
Patients who allocated SP will be treated with S-1 and cis-
platin every 5-week cycle. S-1 will be administered orally ata dose of 40 mg/m2 twice-daily (equivalent to a total daily
dose of 80 mg/m2) for 3 weeks (day 1 to 21). Cisplatin
60 mg/m2 on day 8 of each cycle will be given by intraven-
ous infusion over 2 hours. On the other hand, patients who
allocated XP will be treated with capecitabine and cisplatin
every 3-week cycle. Capecitabine will be administered orally
at a dose of 1000 mg/m2 twice-daily (equivalent to a total
daily dose of 2000 mg/m2) for 2 weeks (day 1 to 14).
Cisplatin 80 mg/m2 on day 1 of each cycle will be given by
intravenous infusion over 2 hours.
Treatment continuation is intended until disease pro-
gression or unacceptable toxicity. If treatment continu-
ation with cisplatin is determined to be unfeasible before
any progression is confirmed, continuously monotherapy
of S-1 or capecitabine will be continued until PD.
Follow-up
During treatment under this protocol, patients will have
a physical check-up and a blood examination before
every drug administration. PFS and RR will be moni-
tored by using abdominal CT or MRI every 6 weeks and
by measuring levels of tumor markers CEA and CA19-9.
Translational research project
Translational research will be conducted to elucidate the
clinical utility of the following biomarkers. These bio-
markers will be analyzed Immunohistochemistry (IHC)
and mRNA expression by using tissue specimen. Tumor
tissue samples from primary lesions and/or biopsy ma-
terial will be collected and centralized assessment.
(i) Immunohistochemistry (IHC): Expression of TP,
DPD, ERCC1, Ki67, LGALS4, and CDH17
(ii) mRNA: Expression of TP, DPD, thymidylate
synthase (TS), orotate phosphoribosyltransferase
(OPRT), and excision repair cross-complementation
group1 (ERCC1)
Discussion
Recently, molecular target drugs has resulted in the oppor-
tunity to provide individualized treatment in the field of
AGC. Especially in patients with HER2-positive AGC
(defined as assessed by IHC 3+ on a scale of 0 to 3+, and/or
fluorescence in-situ hybridization; FISH, HER2:CEP17 ratio
≥2.0), ToGA study showed that adding trastuzumab was
significantly improved overall survival comparing with
standard chemotherapy consists of cytotoxic drugs [11].
This study excludes HER2-positive gastric cancer since
these patients should be recommended trastuzumab con-
taining regimen. The individualized treatment for cytotoxic
agents also needs to be developed to have more effect and
less toxicity.
This is the first study to compare two standard regi-
mens for AGC. Additionally, the translational research is
Tsuburaya et al. BMC Cancer 2012, 12:307 Page 5 of 5
http://www.biomedcentral.com/1471-2407/12/307performed to explore the biomarker for chemo-sensitivity
and make the individualized treatment possible. When the
difference of treatment is found in efficacy or safety from
this analysis, we will conduct a phase III trial to examine
the possibility of individualized treatment. We believe the
result of this study will play the important role to prepare
the individualized therapy for advanced gastric cancer in
the near future.
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